Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18760458 | DUAL MODULATOR OF MGLUR5 AND 5-HT2A RECEPTOR, AND USE THEREOF | July 2024 | June 2025 | Allow | 11 | 1 | 0 | No | No |
| 18665923 | FUSED RING DERIVATIVE HAVING MGAT-2 INHIBITORY ACTIVITY | May 2024 | June 2025 | Allow | 13 | 1 | 1 | Yes | No |
| 18662947 | INHIBITORS OF BUNYAVIRIDAE AND USES THEREOF | May 2024 | March 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18659052 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | May 2024 | June 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18640607 | THERAPEUTICALLY ACTIVE STEROIDAL DERIVATIVES | April 2024 | May 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18587730 | CARDIAC SARCOMERE INHIBITORS | February 2024 | October 2024 | Allow | 7 | 0 | 0 | No | No |
| 18587753 | NOVEL SMALL MOLECULE COMPOUND | February 2024 | April 2025 | Allow | 13 | 1 | 0 | No | No |
| 18435744 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | February 2024 | April 2025 | Abandon | 15 | 0 | 1 | No | No |
| 18433950 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | February 2024 | February 2025 | Allow | 13 | 1 | 0 | No | No |
| 18429524 | METHODS OF TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | February 2024 | February 2025 | Abandon | 13 | 0 | 1 | No | No |
| 18413175 | PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOF | January 2024 | August 2024 | Allow | 7 | 0 | 0 | No | No |
| 18409042 | CARRIER-FREE CURCUMIN NANOPARTICLES FOR EGFR-POSITIVE CANCER THERAPY | January 2024 | June 2025 | Allow | 17 | 0 | 1 | No | No |
| 18404478 | N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-c]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | January 2024 | April 2025 | Allow | 16 | 2 | 0 | Yes | No |
| 18538176 | Boronated Multifunctional Targeting Drug Conjugates, Their Uses and Methods for Their Preparation | December 2023 | March 2025 | Abandon | 15 | 0 | 1 | No | No |
| 18524807 | AZABICYCLO AND DIAZEPINE DERIVATIVES | November 2023 | October 2024 | Allow | 11 | 1 | 0 | No | No |
| 18510936 | AMINATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | November 2023 | March 2025 | Allow | 16 | 3 | 1 | Yes | No |
| 18388728 | {5-CHLORO-2-(2-(3-(SUBSTITUTEDPHENYL)-1,2,4-OXADIAZOL-5-YL)ETHYL)PHENYL}(PHENYL)METHANONES AS LARVICIDAL AGENTS | November 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18505713 | CRYSTALLINE IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS | November 2023 | January 2025 | Allow | 14 | 1 | 0 | Yes | No |
| 18386561 | 3-(4-NITROPHENYL)-5-((2-ISOPROPYL-5-METHYLPHENOXY)METHYL)-1,2,4-OXADIAZOLE AS AN ANTI-CANCER AND ANTIMICROBIAL COMPOUND | November 2023 | February 2024 | Allow | 3 | 0 | 0 | No | No |
| 18472147 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | September 2023 | April 2025 | Allow | 19 | 2 | 0 | No | No |
| 18466804 | COMPOSITIONS AND DEVICES OF POLY-4-HYDROXYBUTYRATE | September 2023 | May 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18460337 | HEPATITIS B CORE PROTEIN MODULATORS | September 2023 | December 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18343554 | LYMPH DIRECTING PRODRUGS | June 2023 | February 2025 | Abandon | 20 | 2 | 1 | No | No |
| 18321092 | Triazole N-Linked Carbamoyl Cyclohexyl Acids as LPA Antagonists | May 2023 | August 2024 | Allow | 14 | 1 | 0 | No | No |
| 18199205 | SOLABEGRON ZWITTERION AND USES THEREOF | May 2023 | June 2025 | Allow | 25 | 1 | 0 | No | No |
| 18181046 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | March 2023 | July 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18176571 | 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID AND METHODS OF USE THEREOF | March 2023 | May 2025 | Abandon | 26 | 1 | 1 | No | No |
| 18172690 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | February 2023 | July 2024 | Allow | 17 | 3 | 1 | Yes | No |
| 18111241 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | February 2023 | June 2024 | Allow | 16 | 1 | 0 | No | No |
| 18156316 | PYRAZINOIC ACID CONJUGATES AND HYBRID CONJUGATES | January 2023 | January 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18081409 | ENERGETIC COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | December 2022 | October 2024 | Allow | 22 | 1 | 1 | Yes | No |
| 18064206 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | December 2022 | February 2024 | Allow | 14 | 1 | 0 | No | No |
| 18072501 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | November 2022 | August 2023 | Allow | 9 | 0 | 0 | No | No |
| 18072505 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | November 2022 | August 2023 | Allow | 9 | 0 | 0 | No | No |
| 17990656 | ANTIFUNGAL AGENTS WITH ENHANCED ACTIVITY IN ACIDIC PH | November 2022 | December 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17985531 | CRYSTALLINE IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS | November 2022 | July 2023 | Allow | 8 | 0 | 0 | No | No |
| 17977960 | SUBSTITUTED 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES AND METHODS OF MAKING AND USING SAME | October 2022 | July 2024 | Allow | 21 | 1 | 0 | No | No |
| 17973362 | PHARMACEUTICAL COMPOSITIONS | October 2022 | January 2025 | Allow | 26 | 2 | 0 | No | No |
| 17964003 | INHIBITORS OF OXIDIZED LOW-DENSITY LIPOPROTEIN RECEPTOR 1 AND METHODS OF USE THEREOF | October 2022 | February 2025 | Abandon | 28 | 2 | 1 | No | No |
| 17960199 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | October 2022 | February 2024 | Allow | 16 | 1 | 0 | No | No |
| 17937841 | INHIBITORS OF HEPATITIS B VIRUS | October 2022 | April 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17953622 | N,N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | September 2022 | February 2023 | Allow | 5 | 0 | 0 | Yes | No |
| 17941959 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | September 2022 | October 2023 | Allow | 13 | 0 | 0 | No | No |
| 17820629 | PRODRUGS, ANALOGS OR DERIVATIVES OF KAEMPFEROL AS ANTIVIRAL AGENTS | August 2022 | June 2024 | Abandon | 22 | 1 | 1 | No | No |
| 17797884 | PROBE FOR DETECTION OF CATHEPSIN ACTIVITY | August 2022 | April 2025 | Allow | 32 | 0 | 0 | No | No |
| 17880996 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | August 2022 | June 2024 | Abandon | 23 | 2 | 1 | No | No |
| 17881044 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | August 2022 | September 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17877514 | TARGETED THERAPEUTICS | July 2022 | April 2024 | Abandon | 20 | 0 | 1 | No | No |
| 17813152 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | July 2022 | March 2025 | Allow | 32 | 0 | 1 | No | No |
| 17862963 | THERAPEUTIC COMPOUNDS AND METHODS | July 2022 | February 2024 | Allow | 19 | 1 | 1 | No | No |
| 17786089 | 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | June 2022 | October 2024 | Allow | 28 | 0 | 0 | No | No |
| 17807057 | BICYCLIC COMPOUNDS | June 2022 | December 2023 | Allow | 18 | 1 | 1 | No | No |
| 17744806 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | May 2022 | November 2023 | Allow | 18 | 1 | 0 | No | No |
| 17736895 | CARDIAC SARCOMERE INHIBITORS | May 2022 | July 2023 | Allow | 14 | 0 | 0 | No | No |
| 17734377 | PYRIDINIUM DERIVATIVES MADE BY HYDROTHERMAL SYNTHESIS FOR USE AS ANOLYTES IN ELECTROCHEMICAL CELLS | May 2022 | December 2024 | Allow | 31 | 2 | 1 | Yes | No |
| 17710911 | VOLTAGE SENSITIVE DYES | March 2022 | March 2025 | Abandon | 36 | 1 | 1 | No | No |
| 17699606 | AZABICYCLO AND DIAZEPINE DERIVATIVES | March 2022 | September 2023 | Allow | 18 | 1 | 0 | No | No |
| 17693527 | BENZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | March 2022 | March 2025 | Allow | 36 | 2 | 1 | No | No |
| 17672508 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | February 2022 | March 2024 | Allow | 25 | 1 | 1 | No | No |
| 17669117 | SUBSTITUTED IMIDAZOQUINOLINES AS AGONISTS OF TLR7 | February 2022 | January 2024 | Allow | 23 | 2 | 0 | No | No |
| 17633655 | ANTIMALARIAL AGENTS | February 2022 | January 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17590503 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | February 2022 | February 2024 | Allow | 24 | 2 | 1 | No | No |
| 17631212 | DUAL MODULATOR OF MGLUR5 AND 5-HT2A RECEPTOR, AND USE THEREOF | January 2022 | March 2024 | Allow | 26 | 2 | 0 | No | No |
| 17581740 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | January 2022 | May 2022 | Abandon | 4 | 1 | 0 | No | No |
| 17626516 | CANNABINOID DERIVATIVES | January 2022 | August 2024 | Allow | 31 | 2 | 1 | No | No |
| 17573081 | THERAPEUTICALLY ACTIVE STEROIDAL DERIVATIVES | January 2022 | January 2024 | Allow | 24 | 1 | 1 | No | No |
| 17573405 | TRNA SYNTHETASE INHIBITORS | January 2022 | November 2023 | Abandon | 22 | 0 | 1 | No | No |
| 17558975 | N,N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | December 2021 | July 2024 | Allow | 31 | 1 | 0 | No | No |
| 17537142 | NOVEL SMALL MOLECULE COMPOUND | November 2021 | October 2023 | Allow | 22 | 1 | 0 | No | No |
| 17525010 | FUSED RING DERIVATIVE HAVING MGAT-2 INHIBITORY ACTIVITY | November 2021 | March 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17610997 | CARBONATE COMPOUND CONTAINING FLUOROSULFONYL GROUP, AND PREPARATION METHOD AND USE OF SAME | November 2021 | October 2024 | Allow | 35 | 1 | 0 | No | No |
| 17607447 | CRYSTAL FORM OF WEE1 INHIBITOR COMPOUND AND USE THEREOF | October 2021 | January 2025 | Allow | 38 | 1 | 0 | No | No |
| 17484876 | DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION AND METHODS OF USE THEREOF | September 2021 | November 2024 | Abandon | 38 | 2 | 1 | No | No |
| 17448482 | TYK2 INHIBITORS AND USES THEREOF | September 2021 | November 2024 | Allow | 38 | 2 | 1 | No | No |
| 17448215 | Targeting mitochondrial dynamics by mitochondrial fusion promoter M1 as a treatment strategy for nervous system injury | September 2021 | March 2024 | Allow | 30 | 2 | 1 | No | No |
| 17447648 | TYK2 INHIBITORS AND USES THEREOF | September 2021 | July 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17471936 | SULFUR (VI) FLUORIDE COMPOUNDS AND METHODS FOR THE PREPARATION THEREOF | September 2021 | May 2025 | Allow | 44 | 1 | 1 | No | No |
| 17470678 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | September 2021 | November 2023 | Allow | 26 | 1 | 0 | No | No |
| 17466770 | COMPOSITIONS AND METHODS OF TREATMENT FOR TINEA PEDIS | September 2021 | November 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17435253 | HERBICIDAL COMPOUNDS | August 2021 | March 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17412135 | INERT SOLUTION-PROCESSABLE MOLECULAR CHROMOPHORES FOR ORGANIC ELECTRONIC DEVICES | August 2021 | April 2024 | Allow | 32 | 2 | 0 | Yes | No |
| 17386098 | Pharmaceutical Compositions For Combination Therapy | July 2021 | June 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17374460 | SUBSTRATES FOR COVALENT TETHERING OF PROTEINS TO FUNCTIONAL GROUPS OR SOLID SURFACES | July 2021 | September 2024 | Allow | 39 | 2 | 1 | No | No |
| 17305537 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | July 2021 | October 2023 | Allow | 27 | 1 | 0 | No | No |
| 17421944 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | July 2021 | April 2025 | Allow | 45 | 1 | 1 | No | No |
| 17368418 | CLASS OF MU-OPIOID RECEPTOR AGONISTS | July 2021 | November 2023 | Abandon | 28 | 2 | 0 | No | No |
| 17362763 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | June 2021 | December 2022 | Allow | 17 | 0 | 0 | No | No |
| 17362283 | METHOD FOR PREPARING 3,7-BIS(DIMETHYLAMINO)PHENOTHIAZIN-5-YLIUM IODIDE | June 2021 | October 2023 | Allow | 27 | 2 | 0 | Yes | No |
| 17350066 | PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOF | June 2021 | October 2023 | Allow | 28 | 1 | 0 | No | No |
| 17343334 | DEUTERATED PROTEASE INHIBITORS | June 2021 | August 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17331959 | STEREOSELECTIVE SYNTHESIS OF INTERMEDIATE FOR PREPARATION OF HETEROCYCLIC COMPOUND | May 2021 | February 2023 | Allow | 20 | 0 | 0 | No | No |
| 17309434 | OPHTHALMIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISEASES AND EYE DISEASES | May 2021 | April 2023 | Abandon | 22 | 2 | 0 | No | No |
| 17293787 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | May 2021 | March 2023 | Allow | 22 | 1 | 1 | No | No |
| 17318329 | INHIBITORS OF BUNYAVIRIDAE AND USES THEREOF | May 2021 | February 2024 | Allow | 33 | 3 | 1 | No | No |
| 17292951 | METHOD OF PRODUCING ACRYLONITRILE DIMER | May 2021 | May 2025 | Allow | 48 | 0 | 1 | No | No |
| 17292887 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | May 2021 | May 2024 | Allow | 36 | 0 | 1 | No | No |
| 17302502 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | May 2021 | January 2023 | Allow | 20 | 0 | 1 | No | No |
| 17241627 | CARBORANE COMPOUNDS AND METHODS OF USE THEREOF | April 2021 | June 2023 | Allow | 26 | 1 | 0 | No | No |
| 17239583 | PLEUROMUTILIN (E)-4-(1-IMIDAZOYLMETHYL )CINNAMIC ACID ESTER WITH ANTI-DRUG RESISTANT BACTERIA ACTIVITY AND A METHOD OF PREPARING THE SAME | April 2021 | August 2022 | Allow | 16 | 0 | 0 | No | No |
| 17283661 | PROCESS FOR PREPARING IMIDAZOLE DERIVATIVES | April 2021 | February 2025 | Allow | 46 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner OTTON, ALICIA L.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 11.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner OTTON, ALICIA L works in Art Unit 1699 and has examined 523 patent applications in our dataset. With an allowance rate of 80.9%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 28 months.
Examiner OTTON, ALICIA L's allowance rate of 80.9% places them in the 45% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by OTTON, ALICIA L receive 1.71 office actions before reaching final disposition. This places the examiner in the 49% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by OTTON, ALICIA L is 28 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +17.9% benefit to allowance rate for applications examined by OTTON, ALICIA L. This interview benefit is in the 64% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 28.4% of applications are subsequently allowed. This success rate is in the 42% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 52.8% of cases where such amendments are filed. This entry rate is in the 74% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 76.9% of appeals filed. This is in the 64% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 78.1% are granted (fully or in part). This grant rate is in the 91% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 8.6% of allowed cases (in the 95% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 7.6% of allowed cases (in the 84% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.